MDGL vs SGMT
MDGL: Madrigal Pharmaceuticals is a biopharmaceutical company commercializing Rezdiffra, the first and only FDA-approved therapy for adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis. SGMT: Sagimet Biosciences is a clinical-stage biopharmaceutical company developing oral FASN inhibitors for the treatment of moderate to severe acne and MASH.
Side-by-side fundamentals
| Metric | MDGL | SGMT | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $476.91 | $8.92 | |
| Market cap | $11.0B | $554M | |
| Net margin | -30.1% | -1393.8% | MDGL higher |
| Operating margin | -31.3% | -1537.0% | MDGL higher |
| ROE FY2025, SEC XBRL | -47.8% | -45.8% | SGMT higher |
| ROA FY2025, SEC XBRL | -22.9% | -43.8% | MDGL higher |
| Debt / equity as of 2026-09-03 | 0.65 | 0.00 | SGMT lower |
| Revenue growth (YoY) as of 2026-09-03 | +149.0% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.63 | 1.83 | |
| 1-year return as of 2026-10-08 close | +9.1% | +22.0% | SGMT higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.